Pulse Biosciences Q2 Adj EPS $(0.19) Beats $(0.22) Estimate
Portfolio Pulse from Benzinga Newsdesk
Pulse Biosciences (NASDAQ:PLSE) reported Q2 adjusted losses of $(0.19) per share, beating the analyst consensus estimate of $(0.22) by 13.64%. This represents a 50% decrease in losses compared to the same period last year.
August 10, 2023 | 8:34 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Pulse Biosciences reported better than expected Q2 results, with losses decreasing by 50% YoY. This could potentially lead to a positive market reaction.
Pulse Biosciences reported a smaller loss than expected for Q2, which is generally seen as a positive sign by investors. The fact that losses decreased by 50% compared to the same period last year further strengthens this positive outlook. Therefore, it is expected that this news could lead to a short-term increase in the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100